Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Myron David Kor who wrote (962)	12/12/1997 6:00:00 PM
From: Slim Pickens	Respond to of 7041

This reaction may be in sympahty with Vivus. A casual observer may think the 25% 4th quarter revenue decline predicted for Vivus is an indication of problems with the overall market for ED drugs. I don't think that's true and I still think Vivus is a great buy. There is room in this market for many players...pills and pellets will exist together and each will bring in customers for the other as patients find the right formula and method for themselves.

To: Myron David Kor who wrote (962)	12/12/1997 6:31:00 PM
From: TradeOfTheDay	Read Replies (1) \| Respond to of 7041

Friday December 12, 5:31 pm Eastern Time Company Press Release SOURCE: Zonagen, Inc. Zonagen Announces Stock Buyback THE WOODLANDS, Texas, Dec. 12 /PRNewswire/ -- Zonagen, Inc. (Nasdaq: ZONA - news) today announced that the Board of Directors has authorized the company to buyback up to $10,000,000 of shares of its common stock. ''As a result of our recently announced worldwide marketing agreement, Zonagen expects to have working capital in excess of our business needs for the near future,'' commented Joseph Podolski, President and CEO. ''At recent price levels the company believes that repurchasing stock represents an attractive investment opportunity and will significantly increase long-term shareholder value.'' The purchases are to be made from time to time in the open market at prevailing market prices. The board will periodically review the stock repurchase program. Zonagen, Inc. specializes in products and services for the management of reproductive health. Its technologies focus on the areas of urology, female health and contraception. In addition to Vasomax, its oral therapeutic for male erectile dysfunction, the Company is developing novel fertility diagnostics and therapeutics, contraceptives and new therapeutics for benign prostatic hyperplasia, sexually transmitted diseases and prostate cancer. Through its wholly owned subsidiary, Fertility Technologies, Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to those relating to the Company's future capital needs and uncertainty of additional funding, uncertainties related to early stage of development, uncertainties related to clinical trial results, substantial dependence on one product, history of operating losses, uncertainty of protection for patents and proprietary technology, governmental regulation, limited sales and marketing and dependence on future collaborators, manufacturing uncertainties and reliance on third parties, competition and technological change, product liability and availability of insurance, and other risks identified in the Company's reports and registration statements, as filed with the Securities and Exchange Commission. SOURCE: Zonagen, Inc.